Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

BackgroundThe Glasgow Microenvironment Score (GMS) combines peritumoural inflammation and tumour stroma percentage to assess interactions between tumour and microenvironment. This was previously demonstrated to associate with colorectal cancer (CRC) prognosis, and now requires validation and assessment of interactions with adjuvant therapy.MethodsTwo cohorts were utilised; 862 TNM I-III CRC validation cohort, and 2912 TNM II-III CRC adjuvant chemotherapy cohort (TransSCOT). Primary endpoints were disease-free survival (DFS) and relapse-free survival (RFS). Exploratory endpoint was adjuvant chemotherapy interaction.ResultsGMS independently associated with DFS (p = 0.001) and RFS (p interaction = 0.013), but not duration (p = 0.64) was dependent on GMS. Furthermore, GMS 0 significantly associated with improved DFS in patients receiving FOLFOX compared with CAPOX (HR 2.23 95% CI 1.19-4.16, p = 0.012).ConclusionsThis study validates the GMS as a prognostic tool for patients with stage I-III colorectal cancer, independent of TNM, with the ability to stratify both low- and high-risk disease. Furthermore, GMS 0 could be employed to identify a subset of patients that benefit from FOLFOX over CAPOX.

Original publication




Journal article


British journal of cancer

Publication Date





786 - 796


School of Medicine, University of Glasgow, Glasgow, UK.


Humans, Colorectal Neoplasms, Organoplatinum Compounds, Fluorouracil, Leucovorin, Antineoplastic Combined Chemotherapy Protocols, Neoplasm Staging, Prognosis, Disease-Free Survival, Chemotherapy, Adjuvant, Cohort Studies, Reproducibility of Results, Aged, Middle Aged, Female, Male, Kaplan-Meier Estimate, Tumor Microenvironment, Capecitabine, Oxaliplatin